Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for preventing and treating toxoplasmosis, coccidiosis and urinary tract infection of pets

A technology for urinary tract infection and toxoplasma, which is applied in the directions of anti-infective drugs, drug combinations, pharmaceutical formulations, etc., can solve problems such as sulfonamide drugs that do not prevent and treat toxoplasma, coccidia and urinary tract infections, and improve drug stability. , The effect of various dosage forms and clear composition

Pending Publication Date: 2022-04-12
佛山市佛丹动物药业有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Since toxoplasmosis, coccidia and urinary tract infections are common diseases in animals, they usually need to be treated with highly targeted sulfonamides. At present, there are only sulfonamides for livestock and poultry in the market, and there is no prevention and treatment of toxoplasma specially designed for pets. , coccidiosis, and sulfa drugs for urinary tract infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1, the pet medicine of this scheme is used for the prevention and treatment of toxoplasma, coccidiosis and urinary tract infection, including active ingredient and auxiliary material composition, wherein active ingredient is selected sulfamethazine, and auxiliary material is selected starch, dextrin, carboxymethyl starch Blend of Sodium and Magnesium Stearate.

[0014] Weigh 500 parts of sulfamethazine as an active ingredient, 72.8 parts of starch, 9.2 parts of dextrin, 12 parts of carboxymethyl starch sodium and 6 parts of magnesium stearate in parts by weight.

[0015] Among them, the starch is divided into three parts, including 12 parts of starch for internal addition, 4.8 parts of starch for pulp preparation, and 56 parts of starch for external addition.

[0016] The preparation process is as follows:

[0017] Step 1: weighing each raw material according to the corresponding weight portion;

[0018] Step 2: After mixing sulfamethazine, starch (internal...

Embodiment 2

[0020] Embodiment 2, the pet medicine of this scheme is used for the prevention and treatment of toxoplasma, coccidia and urinary tract infection, including active ingredients, synergists and auxiliary materials, wherein the active ingredient is selected from sulfamethazine, and the synergist is selected from trimethoprim Pyridine, and the excipients are a mixture of lactose, microcrystalline cellulose, and magnesium stearate.

[0021] Weigh 100 parts of sulfamethazine as an active ingredient, 20 parts of trimethoprim as a synergist, 240 parts of lactose, 234 parts of microcrystalline cellulose, and 6 parts of magnesium stearate as auxiliary materials in parts by weight.

[0022] In the preparation process, the same as in Example 2, the above-mentioned raw materials were selected in corresponding parts by weight, mixed evenly, and then compressed to obtain tablets.

Embodiment 3

[0023] Embodiment 3, the pet medicine of this program is used for the prevention and treatment of toxoplasma, coccidia and urinary tract infection, including active ingredients, synergists and auxiliary materials, wherein the active ingredient is selected from sulfamethazine, and the synergist is selected from trimethoprim Pyridine, and the excipients are a mixture of lactose, microcrystalline cellulose, and magnesium stearate.

[0024] On the selection of raw material, embodiment 3 is identical with embodiment 2, but what two embodiments use is different on the weight part of raw material.

[0025] The raw materials were weighed in parts by weight, including 50 parts of sulfamethazine, 10 parts of trimethoprim, 150 parts of lactose, 84 parts of microcrystalline cellulose, and 6 parts of magnesium stearate.

[0026] In Example 3, in the preparation process, the same as in Example 2, the above-mentioned raw materials were selected in corresponding parts by weight, mixed uniform...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for preventing and treating toxoplasmosis, coccidiosis and urinary tract infection for pets, the medicine comprises the following components in parts by weight: 10-50 parts of an active component, 0-2 parts of a synergist and 10-50 parts of an auxiliary material, and the active component comprises one or a mixture of more of sulfadimidine, sulfadiazine, sulfametoxydiazine and sulfamonomethoxine. The invention belongs to the technical field of preparation of veterinary drugs, and particularly provides a veterinary drug which has very strong antibacterial, bactericidal and toxoplasma gondii killing effects and the like, mutually matched components can enhance the drug effect, the components are clear, the preparation process is simple and convenient to operate, the taste of the drug can be enriched by setting dextrin, lactose and the like in auxiliary materials, pets can eat the drug conveniently, and the veterinary drug is suitable for being eaten by pets. And microcrystalline cellulose and starch are combined and tableted, so that the stability of the medicine can be improved, and the medicine is used for preventing and treating toxoplasma infection, coccidiosis infection and urinary tract infection of pets.

Description

technical field [0001] The invention belongs to the technical field of preparation of veterinary drugs, in particular to a drug for pets to prevent and treat toxoplasma, coccidia and urinary tract infections. Background technique [0002] Toxoplasmosis, also known as toxoplasmosis or toxoplasmosis, is a protozoan disease caused by toxoplasma infecting animals and humans. The disease is mainly characterized by high fever, respiratory and nervous system symptoms, animal death and abortion of pregnant animals, stillbirth, and fetal malformation. Toxoplasmosis is a worldwide zoonotic parasitic protozoan disease, which is widespread in domestic and wild animals. [0003] Since toxoplasmosis, coccidia and urinary tract infections are common diseases in animals, they usually need to be treated with highly targeted sulfonamides. At present, there are only sulfonamides for livestock and poultry in the market, and there is no prevention and treatment of toxoplasma specially designed ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/635A61K31/505A61K47/38A61K47/26A61K47/36A61K9/20A61P33/02A61P33/10A61P13/02
Inventor 程方翔
Owner 佛山市佛丹动物药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com